Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.41 |
| ▸ | GABBR2 | O75899 | 5/20 | 0.39 |
| ▸ | GABBR1 | Q9UBS5 | 5/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24597751 | 1.00 | ESR1 (0.44) | ESR1ESR2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL24597837 | 1.00 | ESR1 (0.44) | ESR1ESR2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL10291752 | 0.91 | ESR1 (0.47) | ESR1ESR2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL20083457 | 0.88 | NR1I2 (0.50) | SLC6A2SLC6A4SLC6A3ADRB2NR1I2 | |
| SCHEMBL8239806 | 0.86 | ADRB2 (0.48) | ESR1ESR2ADRB2GABBR2GABBR1 | |
| SCHEMBL22956046 | 0.85 | ESR1 (0.43) | ESR1ESR2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL19987475 | 0.84 | NR1I2 (0.59) | SLC6A2SLC6A4SLC6A3NR1I2SMN1; SMN2 | |
| SCHEMBL24878661 | 0.83 | GABBR2 (0.53) | ESR1ESR2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11854403 | 0.83 | ESR1 (0.46) | ESR1ESR2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL24878696 | 0.83 | GABBR2 (0.53) | ESR1ESR2SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106496008-A | Method for synthesizing 4- (4-chlorphenyl) cyclohexanone | 上海毕得医药科技有限公司 | 2017-03-15 | — | — | CN | claimed |
| WO-2024108198-A2 | METHODS OF TREATING OBESITY WITH AN MC4R AGONIST | RHYTHM PHARMACEUTICALS, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| US-20230140941-A1 | NON-ATP/CATALYTIC SITE P38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2023-05-11 | — | — | US | disclosed |
| US-11530199-B2 | Analogs for the treatment of disease | INSILICO MEDICINE IP LIMITED (HK) | 2022-12-20 | — | — | US | disclosed |
| US-11078171-B2 | Non-ATP/catalytic site p38 mitogen activated protein kinase inhibitors | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2021-08-03 | — | — | US | disclosed |
| US-20200331874-A1 | NON-ATP/CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS | UNIVERSITY OF MARYLAND, BALTIMORE | 2020-10-22 | — | — | US | disclosed |
| US-20200138827-A1 | SMALL MOLECULE MODULATORS OF HUMAN STING | CURADEV PHARMA LIMITED (GB) | 2020-05-07 | — | — | US | disclosed |
| US-10399932-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-03 | — | — | US | disclosed |
| US-10398706-B2 | Heteroaryldiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-10350208-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ROIVANT SCIENCES GMBH (CH) | 2019-07-16 | — | — | US | disclosed |
| US-10266560-B2 | Bile acid analogs as FXR/TGR5 agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2019-04-23 | — | — | US | disclosed |
| CN-104876955-B | Arginase inhibitor and its treatment use | 马尔斯公司 | 2018-11-23 | — | — | CN | disclosed |
| US-20180193352-A1 | HETEROARYLDIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2018-07-12 | — | — | US | disclosed |
| US-20180079712-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230140941-A1 | NON-ATP/CATALYTIC SITE P38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS | MAPK1, MAPK8, MAPK4 | ESR1 3153/4885ESR2 2810/4885SLC6A2 3701/4885 |
| US-10398706-B2 | Heteroaryldiazepine derivatives as RSV inhibitors | CYP3A5, CYP3A43, CYP3A4 | ESR1 2173/4885ESR2 2156/4885SLC6A2 280/4885 |
| US-11078171-B2 | Non-ATP/catalytic site p38 mitogen activated protein kinase inhibitors | MAPK1, MAPK8, MAPK4 | ESR1 2684/4885ESR2 2363/4885SLC6A2 3954/4885 |
| US-11530199-B2 | Analogs for the treatment of disease | MAP4K4, MAP4K5, MAP4K2 | ESR1 2568/4885ESR2 1707/4885SLC6A2 1879/4885 |
| US-10266560-B2 | Bile acid analogs as FXR/TGR5 agonists and methods of use thereof | GPBAR1, NR1H4, SLC10A1 | ESR1 1045/4885ESR2 689/4885SLC6A2 1773/4885 |
| US-10350208-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | TPH1, TPH2, HTR1A | ESR1 3323/4885ESR2 2059/4885SLC6A2 109/4885 |
| US-20200138827-A1 | SMALL MOLECULE MODULATORS OF HUMAN STING | STING1, IRF3, CGAS | ESR1 2872/4885ESR2 1353/4885SLC6A2 4743/4885 |
| US-10399932-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | IDO1, IDO2, INMT | ESR1 2700/4885ESR2 1201/4885SLC6A2 1080/4885 |
| US-20180193352-A1 | HETEROARYLDIAZEPINE DERIVATIVES AS RSV INHIBITORS | CYP3A5, CYP3A43, CYP3A4 | ESR1 2173/4885ESR2 2156/4885SLC6A2 280/4885 |
| US-20180079712-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | IDO1, IDO2, INMT | ESR1 2700/4885ESR2 1201/4885SLC6A2 1080/4885 |
| US-20200331874-A1 | NON-ATP/CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS | MAPK1, MAPK8, MAPK4 | ESR1 2684/4885ESR2 2363/4885SLC6A2 3954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.